TRIB

Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.

Wall Street analysts forecast TRIB stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TRIB is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Trinity Biotech PLC revenue for the last quarter amounts to 15.15M USD, increased 3.24 % YoY.

Trinity Biotech PLC. EPS for the last quarter amounts to -0.02 USD, decreased -90.91 % YoY.

Trinity Biotech PLC (TRIB) has 398 emplpoyees as of December 15 2025.

Today TRIB has the market capitalization of 19.94M USD.